Inactive Instrument

Abattis Bioceuticals Corp. Stock Canadian Securities Exchange

Equities

ATT

CA00258G1037

Healthcare Facilities & Services

Sales 2018 8.37K 6.08K Sales 2019 357K 259K Capitalization 8.62M 6.26M
Net income 2018 -78M -56.65M Net income 2019 -3M -2.18M EV / Sales 2018 5,778 x
Net cash position 2018 9.1M 6.61M Net cash position 2019 2.25M 1.63M EV / Sales 2019 17.8 x
P/E ratio 2018
-0.57 x
P/E ratio 2019
-2.8 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 99.64%
More Fundamentals * Assessed data
Dynamic Chart
Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2019 CI
Abattis Bioceuticals Corp. Announces Board Changes CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of NutriVida Corp. CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Third Quarter Ended June 30, 2019 CI
Abattis Bioceuticals Corp.'s Equity Buyback announced on August 7, 2018, has expired. CI
Abattis Bioceuticals Corp. Reports Earnings Results for the Full Year Ended September 30, 2018 CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of Winston Resources Inc.. CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) completed the acquisition of Pro Natura BV from The Catalyst Capital Group Inc. CI
Abattis Bioceuticals Corp. Announces Management Changes CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) agreed to acquire Pro Natura BV from The Catalyst Capital Group Inc. for €15.7 million. CI
Abattis Bioceuticals Corp. Announces Resignations in Board CI
British Columbia Securities Commission Removes Temporary Order on Abattis Bioceuticals Corp CI
Abattis Bioceuticals Corp Announces Launch of Its New Website and Provide an Operational Update CI
Abattis Bioceuticals Corp. (OTCPK:ATTB.F) signed a letter of intent to acquire NutriVida Corp. for CAD 15 million. CI
Abattis Bioceuticals Corp Signs a Distribution Agreement with Shefield &Sons Tobacconists Inc. to Sell the Abattis Vaporizer Line in all Shefield &Sons Stores Across Canada CI
More news
Managers TitleAgeSince
Director of Finance/CFO - 19-03-31
Chief Operating Officer - 18-10-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member - 18-10-18
Chief Operating Officer - 18-10-31
Director of Finance/CFO - 19-03-31
More insiders
Abattis Bioceuticals Corp. is a Canada-based specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
More about the company